# US 2008/0287690 A1 · Process For (3R, 5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4- [(4-Hydroxy Methyl Phenyl Amino) Carbonyl]-Pyrrol-1-Yl]-3,5-Dihydroxy-Heptanoic Acid Hemi Calcium Salt

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287690 A1
- Document ID: US20080287690A1
- Status: Published application
- Kind: A1
- Application number: 12/092,620
- Filed: 2006-11-07
- Published: 2008-11-20
- Earliest claimed: 2005-11-08
- Assignees: Ranbaxy Laboratories Limited
- Inventors: Vijay Kaul; Gyan Chand Yadav
- Web page: https://patentgrep.com/patent/US20080287690A1

## CPC

- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to processes for the manufacture of (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt.

## Claims

### Claim 1

A method of making 3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt of Formula I,
pharmaceutically acceptable salts, pharmaceutically acceptable solvates, polymorphs, pro-drugs, stereoisomers, tautomeric forms, N-oxides and metabolites thereof, the method comprising:
(a) reacting a compound of Formula II with a compound of Formula III,
to form a compound of Formula of IV (wherein R is alkyl, aryl or arylalkyl);
(b) reacting the compound of Formula IV with benzaldehyde to form a compound of Formula V;
(c) reacting the compound of Formula V with 4-fluorobenzaldehyde to form a compound of Formula VI;
(d) reacting the compound of Formula VI with a compound of Formula VII,
to form the compound of Formula VIII;
(e) deprotecting the compound of Formula VIII to form a compound of Formula IX;
(f) reducing the compound of Formula IX to form a compound of Formula X;
(g) deprotecting the compound of Formula X to form a compound of Formula XI; and
(h) converting the compound of Formula XI to compound of Formula I,
wherein any purification of products of the steps (a) to (h) is carried out without using column chromatography, and the reaction in step (h) involves a one-pot conversion of compound of Formula XI to the calcium salt of Formula I.

### Claim 2 (depends on 1)

The process according to claim 1, wherein step (a) involves reaction in toluene.

### Claim 3 (depends on 1)

The process according to claim 1, wherein step (c) involves triethylamine.

### Claim 4 (depends on 1)

The process according to claim 1, wherein the reaction of step (e) is carried out in one or more solvents selected from acetonitrile, propionitrile, dimethylsulfoxide, dimethylformamide and dimethoxyethane or methanol:tetrahydrofuran (1:3), in presence of sodium hydroxide, at temperatures ranging from about 50 to about 55° C. for about 4-5 hours, or at about 30° C. for about 8-10 hours.

### Claim 5 (depends on 1)

The process according to claim 1, wherein the step (f) is carried out at a temperatures ranging from about 40 to about 45° C. for about 5 hours.

### Claim 6 (depends on 1)

The process according to claim 1, wherein the reaction of step (g) is carried out in methanol: tetrahydrofuran:water (1:11).

### Claim 7 (depends on 1)

The process according to claim 1, wherein the reaction of step (h) is carried out in tetrahydrofuran: de-ionized water (1:1).

### Claim 8 (depends on 1)

The process according to claim 1, wherein the reaction of step (h) is carried out in ethanol:water (4:1) in presence of calcium hydroxide and a phase transfer catalyst selected from tetraalkylammonium halide, tetrabutylammonium hydrogen sulfate, tetrabutylammonium thiocyanate, tetrabutylammonium tetrafluoroborate, benzyltributylammonium chloride and tetraalkylphosphonium halide.

### Claim 9 (depends on 1)

The process according to claim 1, wherein the reaction of step (h) is carried out at a temperature ranging from about 30 to about 50° C. for about 2 to about 8 hours.

### Claim 10 (depends on 1)

The process according to claim 1, wherein the product of step (h) is amorphous.
